Differential effect of the p53 inducers Nutlin-3 and RITA on cell lines with different p53 status

被引：0
|
作者：
Weilbacher, A. [1 ,2 ]
Gutekunst, M. [1 ,2 ]
Oren, M. [3 ]
Aulitzky, W. [4 ]
van der Kuip, H. [1 ,2 ]
机构：
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-7000 Stuttgart, Germany
[2] Univ Tubingen, Stuttgart, Germany
[3] Weizmann Inst Sci, Dept Mol Biol, IL-76100 Rehovot, Israel
[4] Robert Bosch Hosp Stuttgart, Dept Internal Med 2, Stuttgart, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 196
页数：2
相关论文
共 50 条
  • [41] FUNCTIONAL-ANALYSIS OF WT P53 IN 2 P53 NULL-CELL LINES
    SHARP, D
    LEFFET, LM
    BOYLAN, JF
    FASEB JOURNAL, 1995, 9 (03): : A419 - A419
  • [42] Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53null Cell Lines
    Silden, Elisabeth
    Hjelle, Sigrun M.
    Wergeland, Line
    Sulen, Andre
    Andresen, Vibeke
    Bourdon, Jean-Christophe
    Micklem, David R.
    McCormack, Emmet
    Gjertsen, Bjorn Tore
    PLOS ONE, 2013, 8 (02):
  • [43] Telomeric length in individuals and cell lines with altered p53 status
    Kruk, PA
    Bohr, VA
    RADIATION ONCOLOGY INVESTIGATIONS, 1999, 7 (01): : 13 - 21
  • [44] p53 status and radiosensitivity
    Bodis, S
    Pruschy, M
    Glanzmann, C
    Krek, W
    Lowe, SW
    Fisher, DE
    PROGRESS IN RADIO-ONCOLOGY VI, 1998, : 481 - 489
  • [45] Natural and synthetic inhibitors of mTOR blunt the p53 response to low concentrations of actinomycin D but not nutlin-3
    Goudarzi, K. M.
    Nister, M.
    Lindstrom, M. S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S72 - S72
  • [46] Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma
    Tongsen Zheng
    Dalong Yin
    Zhaoyang Lu
    Jiabei Wang
    Yuejin Li
    Xi Chen
    Yingjian Liang
    Xuan Song
    Shuyi Qi
    Boshi Sun
    Changming Xie
    Xianzhi Meng
    Shangha Pan
    Jiaren Liu
    Hongchi Jiang
    Lianxin Liu
    Molecular Cancer, 13
  • [47] The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis
    Florijan, Marijana Knezovic
    Ozretic, Petar
    Bujak, Maro
    Pezze, Laura
    Ciribilli, Yari
    Kastelan, Zeljko
    Slade, Neda
    Hudolin, Tvrtko
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 578.e1 - 578.e10
  • [48] p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
    Chappell, William H.
    Lehmann, Brian D.
    Terrian, David M.
    Abrams, Stephen L.
    Steelman, Linda S.
    McCubrey, James A.
    CELL CYCLE, 2012, 11 (24) : 4579 - 4588
  • [49] Effect of p53 status in radioimmunotherapy Auger
    Piron, Berengere
    Chouin, Nicolas
    Kersual, Nathalie
    Bardis, Manuel
    Pelegrin, Andre
    Pouget, Jean-Pierre
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [50] Induction of p53 protein by carbon-ion and proton beam irradiation in two close human lymphoblastoid cell lines with different p53 status
    Fukushima, S
    Ozeki, S
    Tang, JT
    Koizumi, M
    Matsumura, S
    Inoue, T
    Inoue, T
    Yamazaki, H
    Murayama, S
    Hatanaka, K
    Ejiri, H
    Kasai, K
    ONCOLOGY REPORTS, 1997, 4 (03) : 481 - 484
12345